PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced submission mid-2011 of its acyclovir Lauriad® European registration dossier, upon advice of the Health Authorities. Acyclovir Lauriad® is BioAlliance Pharma second product using the Lauriad® technology and has been developed for the treatment of recurrent herpes labialis in immunocompetent patients. The dossier will be submitted through a European decentralized procedure and will be based on the final positive results of its pivotal phase III clinical trial.
